The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global human microbiome market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 18% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The human microbiome refers to the genes present inside various microorganisms found in the genetic portrait, or metagenome, of humans. It consists of various microorganisms, such as bacteria, fungi, protozoans, non-living viruses and numerous single-celled organisms. These organisms impact human physiology and contribute to the enhancement or impairment of metabolic and immune functions. They are found in the human tissues and are studied for medical advancements and analytical techniques. Microbiomes are utilized in probiotics, prebiotics, pharmaceutical drugs and diagnostic and therapeutic systems for various ailments, such as diabetes, obesity, cancer and metabolic, gastrointestinal, neurological, central nervous system and autoimmune disorders.
The increasing prevalence of chronic lifestyle diseases and infections due to microbial dysbiosis across the globe is one of the key factors driving the market growth. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. The growth of the market can also be attributed to the increasing emphasis on the development of human microbiome therapeutics with enhanced efficacy. For instance, human gut microbiomes are being developed in specific combinations for the effective treatment of various gastrointestinal ailments. In line with this, the onset of the coronavirus (COVID-19) pandemic is also providing a thrust to the market growth. Researchers are extensively studying the lung microbiomes to analyze the severity of the infections and develop appropriate therapeutics and vaccines. Additionally, various advancements, such as the development of target-specific microbiome-based therapies, are also favoring the growth of the market. Other factors, including extensive research and development (R&D) activities, along with significant growth in the pharmaceutical industry, especially in the developing economies, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global human microbiome market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product, application and disease type.
Breakup by Product:
Breakup by Application:
Breakup by Disease Type:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 4D pharma plc, Atlas Biomed Group Limited, BIOHM , BiomX , Bione , DayTwo Inc., ENTEROME , Ferring B.V., Finch Therapeutics, Second Genome Inc., SynBioBeta LLC, Synthetic Biologics Inc., Vedanta Biosciences Inc. and Viome Inc.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Application, Disease Type, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||4D pharma plc, Atlas Biomed Group Limited, BIOHM , BiomX , Bione , DayTwo Inc., ENTEROME , Ferring B.V., Finch Therapeutics, Second Genome Inc., SynBioBeta LLC, Synthetic Biologics Inc., Vedanta Biosciences Inc. and Viome Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at